Cost Effectiveness of Voretigene Neparvovec for RPE65-Mediated Inherited Retinal Degeneration in Germany

PURPOSE: Voretigene Neparvovec-rzyl (VN) is the first available treatment for biallelic RPE65 mutation-associated inherited retinal degeneration, which is usually associated with infancy-onset severe visual impairment and complete blindness during the third life decade. We aim to estimate the cost e...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhrmann, Matthias Fritz, Lorenz, Birgit, Gissel, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442871/
https://www.ncbi.nlm.nih.gov/pubmed/32879773
http://dx.doi.org/10.1167/tvst.9.9.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442871/
https://www.ncbi.nlm.nih.gov/pubmed/32879773
http://dx.doi.org/10.1167/tvst.9.9.17

Ejemplares similares